© 2000 by Oxford University Press
Journal of the National Cancer Institute, Vol. 92, No. 16, 1321-1329,
August 16, 2000
© 2000 Oxford University Press
Decision Framework for Chemotherapeutic Interventions for Metastatic Non-Small-Cell Lung Cancer
Affiliations of authors: J.-M. Berthelot, B. P. Will, Statistics Canada, Ottawa; W. K. Evans, C. C. Earle, L. Bordeleau, Ottawa Regional Cancer Centre, ON, Canada, and University of Ottawa; D. Coyle, Clinical Epidemiology Unit, Loeb Health Research Institute, Civic Campus, Ottawa Hospital.
Correspondence to: William K. Evans, M.D., F.R.C.P.C., Cancer Care Ontario, 620 University Ave., Toronto, ON M5G 2L7, Canada (e-mail: bill.evans{at}cancercare.on.ca).
Background: Best supportive care has long been considered to be the standard therapy for metastatic non-small-cell lung cancer (NSCLC). There is now evidence from randomized trials that a number of chemotherapy regimens can palliate cancer-related symptoms and modestly improve survival. We show how cost-effectiveness 1analyses can be used to make choices between different (ambulatory) chemotherapy regimens. Methods: Clinical algorithms describing the diagnosis, staging, and treatment of metastatic NSCLC were incorporated into Statistics Canada's Population Health Model. Using consistent methodology, we assessed the cost-effectiveness of several chemotherapeutic interventions: a combination of vindesine (VDS) plus cisplatin, etoposide (VP-16) plus cisplatin, vinblastine (VLB) plus cisplatin, vinorelbine (Navelbine; NVB) plus cisplatin, paclitaxel (Taxol) plus cisplatin, and gemcitabine (GEM) and NVB alone. We calculated the total chemotherapy costs in 1995 Canadian dollars, the cost per case, the average life-years saved, and the cost per life-year saved. Using the Population Health Model, we then constructed an advanced decision framework that rank-ordered the various treatment regimens so as to optimize benefit below various cost-effectiveness thresholds. Results: One regimen (VLB plus cisplatin) appears to result in better survival and lower health care expenditures than best supportive care. By use of cost-effectiveness thresholds of $25 000 and $50 000 per life-year gained, NVB plus cisplatin is the preferred regimen. When quality of life is considered, however, GEM is preferred to NVB plus cisplatin at a threshold value of $50 000. At thresholds of $75 000 and $100 000, paclitaxel plus cisplatin at a dose of 135 mg/m2 is the preferred regimen. At thresholds of $50 000 and above, best supportive care is the least preferred regimen. Conclusions: This decision framework allows the comparison of different treatment regimens based on various cost-effectiveness thresholds. Our analysis also supports the use of chemotherapy regimens and the abandonment of best supportive care as the standard of care for patients with advanced NSCLC. [J Natl Cancer Inst 2000;92:1321–9].
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  C. A. Dooms, Y. N. Lievens, and J. F. Vansteenkiste Cost-utility analysis of chemotherapy in symptomatic advanced nonsmall cell lung cancer Eur. Respir. J., May 1, 2006; 27(5): 895 - 901. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 F. Kee, T. Owen, and R. Leathem Decision Making in a Multidisciplinary Cancer Team: Does Team Discussion Result in Better Quality Decisions? Med Decis Making, November 1, 2004; 24(6): 602 - 613. [Abstract] [PDF]
|
|
|
|
 |
|
 C. C. Earle Outcomes Research in Lung Cancer J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 56 - 77. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. Erickson A Health Outcomes Framework for Assessing Health Status and Quality of Life: Enhanced Data for Decision Making J Natl Cancer Inst Monographs, October 1, 2004; 2004(33): 168 - 177. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Gridelli, C. Gallo, F. A. Shepherd, A. Illiano, F. Piantedosi, S. F. Robbiati, L. Manzione, S. Barbera, L. Frontini, E. Veltri, et al. Gemcitabine Plus Vinorelbine Compared With Cisplatin Plus Vinorelbine or Cisplatin Plus Gemcitabine for Advanced Non-Small-Cell Lung Cancer: A Phase III Trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group J. Clin. Oncol., August 15, 2003; 21(16): 3025 - 3034. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
G. A. Silvestri, S. Knittig, J. S. Zoller, and P. J. Nietert Importance of Faith on Medical Decisions Regarding Cancer Care J. Clin. Oncol., April 1, 2003; 21(7): 1379 - 1382. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A Clegg, D A Scott, P Hewitson, M Sidhu, and N Waugh Clinical and cost effectiveness of paclitaxel, docetaxel, gemcitabine, and vinorelbine in non-small cell lung cancer: a systematic review Thorax, January 1, 2002; 57(1): 20 - 28. [Abstract] [Full Text] [PDF]
|
|